Real-World test: can stronger doses tame stubborn hives?
NCT ID NCT04583475
Summary
This study looked at how doctors adjust treatment for adults with chronic hives (urticaria) who take the medication omalizumab (Xolair). Researchers followed 163 patients to see how often doctors increased the dose or gave shots more frequently to improve control. The main goal was to see if these treatment changes led to better symptom control and quality of life for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPONTANEOUS URTICARIA, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hop Claude Huriez Chu Lille
Lille, 59037, France
Conditions
Explore the condition pages connected to this study.